Testosterone enanthate therapy is effective and independent of SRD5A2 and AR gene polymorphisms in boys with micropenis

被引:16
|
作者
Ishii, T
Sasaki, G
Hasegawa, T
Sato, S
Matsuo, N
Ogata, T
机构
[1] Natl Res Inst Child Hlth & Dev, Dept Endocrinol & Metab, Tokyo 1548567, Japan
[2] Keio Univ, Sch Med, Dept Pediat, Tokyo 108, Japan
来源
JOURNAL OF UROLOGY | 2004年 / 172卷 / 01期
关键词
penis/abnormalities; testosterone; 5-alpha-reductase; polymorphism (genetics);
D O I
10.1097/01.ju.0000129005.84831.1e
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: We report penile length (PL) responses to testosterone enanthate (TE) therapy for micropenis, and the relevance of the V89L polymorphism of SRD5A2 encoding the 5alpha-reductase type 2 and CAG repeat length polymorphism of AR encoding the androgen receptor. Materials and Methods: A total of 53 Japanese boys with micropenis (less than -2.0 SD) 0 to 13 years old who had no SRD5A2 or AR mutation were examined. TE was given at a dosage of 25 mg intramuscularly, and PL was measured at least 4 weeks after the injection. The 2 polymorphisms were determined by direct sequencing. Results: PLs became -2.0 SD or greater in all the boys after TE therapy (1 injection in 4 boys, 2 in 28, 3 in 19 and 4 in 2), with a significant increase in the medians of PLs (from 2.5 to 3.5 cm, p <0.0001) and SD score, (from -2.6 to -0.7, p <0.0001). The increment in actual PL at the first injection ranged from 0.2 to 1.5 cm (median 0.6) and was independent of age (r = 0.22, p = 0.12) and body surface area (r = 0.11, p =0.43), while that in PL SD score at the first injection ranged from 0.3 to 2.5 (1.0) and was inversely correlated with age (r = -0.33, p = 0.02) and body surface area (r = -0.37, p = 0.008). The actual PL increment at the first injection was also unrelated to initial PL (r = -0.03, p = 0.81). The median of actual PL increments at the first injection was similar among boys with V/V, V/L and L/L genotypes of SRD5A2 (0.6 cm in 18, 0.7 cm in 30 and 0.5 cm in 5, respectively, p = 0.77), and between boys with and without long CAG repeats (26 or greater) of AR (0.65 cm in 6 and 0.6 cm in 47, respectively, p = 0.77). In addition, there was no significant correlation between actual PL increment at the first injection and CAG repeat length (r = 0.06, p = 0.67). Conclusions: Our results suggest that administration of 25 mg TE is effective for micropenis in prepubertal boys with no SRD5A2 or AR mutation, with variable but significant PL increments, and that the penile responsiveness to TE therapy is independent of the V89L and the CAG repeat length polymorphisms.
引用
收藏
页码:319 / 323
页数:5
相关论文
共 50 条
  • [41] Clinical Characterization and Analysis of the SRD5A2 Gene in Six Korean Patients with 5α-Reductase Type 2 Deficiency
    Ko, Jung Min
    Cheon, Chong-Kun
    Kim, Gu-Hwan
    Kim, Sung Hoon
    Kim, Kun Suk
    Yoo, Han-Wook
    HORMONE RESEARCH IN PAEDIATRICS, 2010, 73 (01): : 41 - 48
  • [42] Novel mutations of the SRD5A2 and AR genes in Thai patients with 46, XY disorders of sex development
    Ittiwut, Chupong
    Pratuangdejkul, Jaturong
    Supornsilchai, Vichit
    Muensri, Sasipa
    Hiranras, Yodporn
    Sahakitrungruang, Taninee
    Watcharasindhu, Suttipong
    Suphapeetiporn, Kanya
    Shotelersuk, Vorasuk
    JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, 2017, 30 (01): : 19 - 26
  • [43] Mutational Analysis of SRD5A2 and AR Genes in Indian Children with 46 XY Disorders of Sex Development
    Kumar, Anil
    Faruq, Mohd
    Werner, Ralf
    Sharma, Rajni
    Jain, Vandana
    HORMONE RESEARCH IN PAEDIATRICS, 2018, 90 : 640 - 641
  • [44] A polymorphism in 5-alpha-reductase (SRD5A2) gene shows novel association with prostate cancer
    Minarik, M.
    Benesova, L.
    Fantova, L.
    Heracek, J.
    Urban, M.
    Loukola, A.
    EUROPEAN UROLOGY SUPPLEMENTS, 2007, 6 (02) : 49 - 49
  • [45] A CASE OF SEX DEVELOPMENT DISORDER DUE TO A NOVEL MUTATION IN 5 ALFA REDUCTASE (SRD5A2) GENE
    Mengen, Eda
    Kotan, L. Damla
    Yuksel, Bilgin
    Topaloglu, A. Kemal
    HORMONE RESEARCH IN PAEDIATRICS, 2017, 88 : 370 - 370
  • [46] Mutational analysis of SRD5A2: From gene to functional kinetics in individuals with steroid 5α-reductase 2 deficiency
    Ramos, L.
    Vilchis, F.
    Chavez, B.
    Mares, L.
    JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2020, 200
  • [47] Longer TA repeat but not V89L polymorphisms in the SRD5A2 gene may confer acne risk in the Chinese population
    Hu, Xue
    Ding, Wei
    Jin, Xinye
    Wang, Jia
    Zou, Dajin
    Chen, Yue
    POSTEPY DERMATOLOGII I ALERGOLOGII, 2018, 35 (01): : 33 - 38
  • [48] The association between polymorphisms in the CYP17 and 5α-reductase (SRD5A2) genes and serum androgen concentrations in men
    Allen, NE
    Forrest, MS
    Key, TJ
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2001, 10 (03) : 185 - 189
  • [49] Association of prostate cancer risk and aggressiveness to androgen pathway genes:: SRD5A2, CYP17, and the AR
    Cicek, MS
    Conti, DV
    Curran, A
    Neville, PJ
    Paris, PL
    Casey, G
    Witte, JS
    PROSTATE, 2004, 59 (01): : 69 - 76
  • [50] GENETIC-VARIABILITY OF THE HUMAN SRD5A2 GENE - IMPLICATIONS FOR PROSTATE-CANCER RISK
    REICHARDT, JKV
    MAKRIDAKIS, N
    HENDERSON, BE
    YU, MC
    PIKE, MC
    ROSS, RK
    CANCER RESEARCH, 1995, 55 (18) : 3973 - 3975